Cargando…
Experience with the use of siltuximab in patients with SARS-CoV-2 infection
OBJECTIVES: The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that received siltuximab according to a protocol that aimed to early block the activity of IL-6 to avoid the progression of the inflammatory flare. PATIENTS AND METHODS: Retrospective re...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Quimioterapia
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329576/ https://www.ncbi.nlm.nih.gov/pubmed/33982984 http://dx.doi.org/10.37201/req/045.2021 |
_version_ | 1783732536731500544 |
---|---|
author | Meira, Fernanda Albiach, Laia Carbonell, Cristina Martín-Oterino, José-Ángel Martín-Ordiales, Mercedes Linares, Laura Macaya, Irene Agüero, Daiana Ambrosioni, Juan Bodro, Marta Cardozo, Celia Chumbita, Mariana De la Mora, Lorena García-Pouton, Nicole Garcia-Vidal, Carolina González-Cordón, Ana Hernández-Meneses, Marta Inciarte, Alexy Laguno, Montserrat Leal, Lorna Morata, Laura Puerta-Alcalde, Pedro Rico, Verónica Letona, Laura Cózar-Llistó, Alberto Dueñas, Gerard Solá, Montserrat Torres, Berta Rojas, Jhon Moreno, Antonio Moreno-García, Estela Torres, Manuel Martínez, José A Soriano, Alex García, Felipe |
author_facet | Meira, Fernanda Albiach, Laia Carbonell, Cristina Martín-Oterino, José-Ángel Martín-Ordiales, Mercedes Linares, Laura Macaya, Irene Agüero, Daiana Ambrosioni, Juan Bodro, Marta Cardozo, Celia Chumbita, Mariana De la Mora, Lorena García-Pouton, Nicole Garcia-Vidal, Carolina González-Cordón, Ana Hernández-Meneses, Marta Inciarte, Alexy Laguno, Montserrat Leal, Lorna Morata, Laura Puerta-Alcalde, Pedro Rico, Verónica Letona, Laura Cózar-Llistó, Alberto Dueñas, Gerard Solá, Montserrat Torres, Berta Rojas, Jhon Moreno, Antonio Moreno-García, Estela Torres, Manuel Martínez, José A Soriano, Alex García, Felipe |
author_sort | Meira, Fernanda |
collection | PubMed |
description | OBJECTIVES: The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that received siltuximab according to a protocol that aimed to early block the activity of IL-6 to avoid the progression of the inflammatory flare. PATIENTS AND METHODS: Retrospective review of the first 31 patients with SARS-CoV-2 treated with siltuximab, in Hospital Clinic of Barcelona or Hospital Universitario Salamanca, from March to April 2020 with positive polymerase-chain reaction (PCR) from a nasopharyngeal swab. RESULTS: The cohort included 31 cases that received siltuximab with a median (IQR) age of 62 (56-71) and 71% were males. The most frequent comorbidity was hypertension (48%). The median dose of siltuximab was 800 mg ranging between 785 and 900 mg. 7 patients received siltuximab as a salvage therapy after one dose of tocilizumab. At the end of the study, a total of 26 (83.9) patients had been discharged alive and the mortality rate was 16.1% but only 1 out of 24 that received siltuximab as a first line option (4%). CONCLUSIONS: Siltuximab is a well-tolerated alternative to tocilizumab when administered as a first line option in patients with COVID-19 pneumonia within the first 10 days from symptoms onset and high C-reactive protein. |
format | Online Article Text |
id | pubmed-8329576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Sociedad Española de Quimioterapia |
record_format | MEDLINE/PubMed |
spelling | pubmed-83295762021-08-20 Experience with the use of siltuximab in patients with SARS-CoV-2 infection Meira, Fernanda Albiach, Laia Carbonell, Cristina Martín-Oterino, José-Ángel Martín-Ordiales, Mercedes Linares, Laura Macaya, Irene Agüero, Daiana Ambrosioni, Juan Bodro, Marta Cardozo, Celia Chumbita, Mariana De la Mora, Lorena García-Pouton, Nicole Garcia-Vidal, Carolina González-Cordón, Ana Hernández-Meneses, Marta Inciarte, Alexy Laguno, Montserrat Leal, Lorna Morata, Laura Puerta-Alcalde, Pedro Rico, Verónica Letona, Laura Cózar-Llistó, Alberto Dueñas, Gerard Solá, Montserrat Torres, Berta Rojas, Jhon Moreno, Antonio Moreno-García, Estela Torres, Manuel Martínez, José A Soriano, Alex García, Felipe Rev Esp Quimioter Original OBJECTIVES: The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that received siltuximab according to a protocol that aimed to early block the activity of IL-6 to avoid the progression of the inflammatory flare. PATIENTS AND METHODS: Retrospective review of the first 31 patients with SARS-CoV-2 treated with siltuximab, in Hospital Clinic of Barcelona or Hospital Universitario Salamanca, from March to April 2020 with positive polymerase-chain reaction (PCR) from a nasopharyngeal swab. RESULTS: The cohort included 31 cases that received siltuximab with a median (IQR) age of 62 (56-71) and 71% were males. The most frequent comorbidity was hypertension (48%). The median dose of siltuximab was 800 mg ranging between 785 and 900 mg. 7 patients received siltuximab as a salvage therapy after one dose of tocilizumab. At the end of the study, a total of 26 (83.9) patients had been discharged alive and the mortality rate was 16.1% but only 1 out of 24 that received siltuximab as a first line option (4%). CONCLUSIONS: Siltuximab is a well-tolerated alternative to tocilizumab when administered as a first line option in patients with COVID-19 pneumonia within the first 10 days from symptoms onset and high C-reactive protein. Sociedad Española de Quimioterapia 2021-05-13 2021 /pmc/articles/PMC8329576/ /pubmed/33982984 http://dx.doi.org/10.37201/req/045.2021 Text en © The Author 2021 https://creativecommons.org/licenses/by-nc/4.0/Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). |
spellingShingle | Original Meira, Fernanda Albiach, Laia Carbonell, Cristina Martín-Oterino, José-Ángel Martín-Ordiales, Mercedes Linares, Laura Macaya, Irene Agüero, Daiana Ambrosioni, Juan Bodro, Marta Cardozo, Celia Chumbita, Mariana De la Mora, Lorena García-Pouton, Nicole Garcia-Vidal, Carolina González-Cordón, Ana Hernández-Meneses, Marta Inciarte, Alexy Laguno, Montserrat Leal, Lorna Morata, Laura Puerta-Alcalde, Pedro Rico, Verónica Letona, Laura Cózar-Llistó, Alberto Dueñas, Gerard Solá, Montserrat Torres, Berta Rojas, Jhon Moreno, Antonio Moreno-García, Estela Torres, Manuel Martínez, José A Soriano, Alex García, Felipe Experience with the use of siltuximab in patients with SARS-CoV-2 infection |
title | Experience with the use of siltuximab in patients with SARS-CoV-2 infection |
title_full | Experience with the use of siltuximab in patients with SARS-CoV-2 infection |
title_fullStr | Experience with the use of siltuximab in patients with SARS-CoV-2 infection |
title_full_unstemmed | Experience with the use of siltuximab in patients with SARS-CoV-2 infection |
title_short | Experience with the use of siltuximab in patients with SARS-CoV-2 infection |
title_sort | experience with the use of siltuximab in patients with sars-cov-2 infection |
topic | Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329576/ https://www.ncbi.nlm.nih.gov/pubmed/33982984 http://dx.doi.org/10.37201/req/045.2021 |
work_keys_str_mv | AT meirafernanda experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT albiachlaia experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT carbonellcristina experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT martinoterinojoseangel experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT martinordialesmercedes experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT linareslaura experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT macayairene experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT aguerodaiana experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT ambrosionijuan experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT bodromarta experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT cardozocelia experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT chumbitamariana experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT delamoralorena experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT garciapoutonnicole experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT garciavidalcarolina experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT gonzalezcordonana experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT hernandezmenesesmarta experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT inciartealexy experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT lagunomontserrat experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT leallorna experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT moratalaura experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT puertaalcaldepedro experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT ricoveronica experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT letonalaura experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT cozarllistoalberto experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT duenasgerard experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT solamontserrat experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT torresberta experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT rojasjhon experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT morenoantonio experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT morenogarciaestela experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT torresmanuel experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT martinezjosea experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT sorianoalex experiencewiththeuseofsiltuximabinpatientswithsarscov2infection AT garciafelipe experiencewiththeuseofsiltuximabinpatientswithsarscov2infection |